Efficacy and Safety of Oral Febuxostat in Participants With Gout

Inclusion Criteria: * Has one or more of the American Rheumatism Association criteria for the diagnosis of gout. * Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study. * Must have a serum urate level greater than or equal to 8.0 milligram per deciliter (mg/dL). Exclusion Criteria: * Have a severe, unstable, or life threatening medical condition that would likely prevent them from completing this study. * Has a known body reaction to febuxostat, allopurinol, naproxen, any other non-steroidal anti-inflammatory drug (NSAID), aspirin, lansoprazole, colchicine, or any components in their formulation. * History of xanthinuria. * Alcohol consumption greater than 14/week. * History of significant concomitant illness. * Active liver or peptic ulcer disease. * Has rheumatoid arthritis requiring treatment. * Has estimated creatinine clearance less than 30 milliliter per minute (mL/min) calculated using the Cockcroft-Gault formula corrected for ideal body weight. * Requires therapy with any other urate-lowering drug other than the study drug; long-term use of NSAIDs and COX-2 inhibitors; salicylates; thiazide diuretics; losartan; azathioprine; mercaptopurine; theophylline; intravenous (IV) colchicine; cyclosporine; cyclophosphamide; pyrazinamide; sulfamethoxazole;trimethoprim.